A Phase 2 interventional study of Mirikizumab in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 37 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 12th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 2, and was the 5th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2020.
This study's enrollment of 26 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 15th largest by enrollment, is the only one that started in 2020, is one of 8 in phase 2, and was the 5th registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab. The study lasted about 52 weeks and included up to 18 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants (≤40 kg weight) received 5 mg/kg mirikizumab given as an IV infusion every 4 weeks (Q4W) on weeks 0, 4, 8 for 12 weeks.
Drug: Mirikizumab
Participants (≤40 kg weight) received 10 mg/kg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.
Drug: Mirikizumab
Participants (\>40 kg weight) received 300 mg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.
Drug: Mirikizumab
Participants (≤20 kg weight) who were responders to mirikizumab at week 12 in induction received 50 mg subcutaneously (SC) Q4W from week 12 through week 48 or until loss of response was confirmed.
Drug: Mirikizumab
Participants (\>20 to ≤40 kg weight) who were responders to mirikizumab at week 12 in induction received 100 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.
Drug: Mirikizumab
Participants (\>40 kg weight) who were responders to mirikizumab at week 12 in induction received 200 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.
Drug: Mirikizumab
Participants (≤40 kg) who were non responders to miri at Week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 50 mg miri (≤20 kg weight) SC Q4W through week 48 or until loss of response was confirmed.
Drug: Mirikizumab
Participants (≤40 kg) who were non responders to miri at week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 100 mg miri (\>20 to ≤40 kg weight) SC Q4W through week 48 or until loss of response was confirmed.
Drug: Mirikizumab
Participants (\>40 kg) who were non responders to miri at week 12 in induction received 300 mg SC Q4W for 12 weeks or discontinued after repeat induction, then received 200 mg miri SC Q4W through week 48 or until loss of response was confirmed.
Drug: Mirikizumab
Administered IV and SC
Also known as: LY3074828
Pharmacokinetics (PK): Clearance of Mirikizumab
Clearance of mirikizumab was evaluated. The PK of mirikizumab is characterized at interim analysis points using mixed-effect (population PK) modelling approaches using the available induction and maintenance mirikizumab concentration data.
Time frame: Predose on week 4, 8, 12,16, 24, 36, 52 and post dose on week 0 and 8
Percentage of Participants in Clinical Remission
Clinical remission at week 52 is defined as achieving a 9-point modified Mayo score (MMS) for rectal bleeding (RB) = 0, stool frequency (SF) = 0 or 1 and endoscopy (ES) = 0 or 1 (excluding friability). The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration.
Time frame: Week 52
Percentage of Participants in Clinical Response
Clinical response at week 52 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of ≥2 points and ≥30% from baseline with either a decrease of rectal bleeding subscore of ≥1 or rectal bleeding subscore of 0 or 1. The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)
Time frame: Week 52
Percentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids
Corticosteroid-free clinical remission was defined as an SF subscore = 0 or 1, RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 52-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: Week 52
Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)
The PUCAI is a clinician-administered, 6-item questionnaire that measures: abdominal pain; RB; stool consistency; number of stools; nocturnal stools; and activity level. For PUCAI score all items are answered as an average over the 'past 2 days'. A total disease activity score is calculated from 0 to 85, with Severe 65-85; Moderate:35-60; Mild:10-30, and None:\<10. The clinician will record the participant or caregiver/legal guardian responses for the PUCAI electronically as source data in the tablet device at appropriate visits. PUCAI clinical remission is defined as a PUCAI score of \<10 points.
Time frame: Week 52
Percentage of Participants in Clinical Response Based on the PUCAI
PUCAI clinical response is defined as a reduction in baseline PUCAI score of ≥20 points.
Time frame: Week 52
Percentage of Participants in Endoscopic Remission
Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 52. ES subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
Time frame: Week 52
Percentage of Participants in Symptomatic Remission
Symptomatic remission at week 52 is defined as a Mayo score for RB=0, SF=0 or 1 with ≥ 1 point decrease from baseline. SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).
Time frame: Week 52
Height Velocity (in Centimeters/Year)
Observed height velocity by gender and age group was calculated. Age groups for which this was summarized were 2 to \<8, 8 to \<12, and 12 to \<18. Observed height velocity by gender and age group was calculated at baseline according to the following formula: (Present Height \[cm\] - Previous Height \[cm\])/Interval (months) Between Measurements × 12.
Time frame: Week 52
Change From Baseline in Body Weight
Change from Baseline in body weight by gender and age group was calculated.
Time frame: Baseline, Week 52
Percentage of Participants With Histologic-Endoscopic Mucosal Remission
Histologic-endoscopic mucosal remission is defined as achieving both histologic remission and endoscopic remission. Histologic remission is defined as Geboes histological subscores of 0 for parameters: 2B (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration).
Time frame: Week 52
Change From Baseline in 7-day Average of Abdominal Pain Numeric Rating Scale (NRS) Score at Week 12
The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.
Time frame: Baseline, Week 12
Change From Baseline in 7-day Average of Abdominal Pain NRS Score at Week 52
The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.
Time frame: Baseline, Week 52
| Milestone | Open Label (OL) Induction Period: 5 Milligram Per Kilogram (mg/kg) Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | OL Maintenance Period: 50 mg Miri Subcutaneous (SC) | OL Maintenance Period: 100 mg Miri SC | OL Maintenance Period: 200 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SC | OL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 5 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 10 | 5 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Open Label (OL) Induction Period: 5 Milligram Per Kilogram (mg/kg) Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | OL Maintenance Period: 50 mg Miri Subcutaneous (SC) | OL Maintenance Period: 100 mg Miri SC | OL Maintenance Period: 200 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SC | OL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 1 | 8 | 9 | 1 | 1 | 6 |
| Completed | 0 | 0 | 0 | 1 | 7 | 8 | 0 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 |
| Withdrew: Withdrawal by parent or guardian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Open Label (OL) Induction Period: 5 Milligram Per Kilogram (mg/kg) Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | OL Maintenance Period: 50 mg Miri Subcutaneous (SC) | OL Maintenance Period: 100 mg Miri SC | OL Maintenance Period: 200 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SC | OL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 5 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 9 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent or guardian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clearance of mirikizumab was evaluated. The PK of mirikizumab is characterized at interim analysis points using mixed-effect (population PK) modelling approaches using the available induction and maintenance mirikizumab concentration data.
| Liters per hour per kilogram (L/hr/kg) | Mirikizumab |
|---|---|
| Pharmacokinetics (PK): Clearance of Mirikizumab | 0.000190 ± 59.74 |
Clinical remission at week 52 is defined as achieving a 9-point modified Mayo score (MMS) for rectal bleeding (RB) = 0, stool frequency (SF) = 0 or 1 and endoscopy (ES) = 0 or 1 (excluding friability). The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration.
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants in Clinical Remission | 0.0 (0.0 to 79.3) | 62.5 (30.6 to 86.3) | 55.6 (26.7 to 81.1) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
Clinical response at week 52 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of ≥2 points and ≥30% from baseline with either a decrease of rectal bleeding subscore of ≥1 or rectal bleeding subscore of 0 or 1. The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants in Clinical Response | 0.0 (0.0 to 79.3) | 75.0 (40.9 to 92.9) | 88.9 (56.5 to 98.0) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
Corticosteroid-free clinical remission was defined as an SF subscore = 0 or 1, RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 52-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/ 100 mg Miri SC | Maintenance Period: 300 mg Miri IV/ 200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids | 0.0 (0.0 to 79.3) | 62.5 (30.6 to 86.3) | 55.6 (26.7 to 81.1) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
The PUCAI is a clinician-administered, 6-item questionnaire that measures: abdominal pain; RB; stool consistency; number of stools; nocturnal stools; and activity level. For PUCAI score all items are answered as an average over the 'past 2 days'. A total disease activity score is calculated from 0 to 85, with Severe 65-85; Moderate:35-60; Mild:10-30, and None:\<10. The clinician will record the participant or caregiver/legal guardian responses for the PUCAI electronically as source data in the tablet device at appropriate visits. PUCAI clinical remission is defined as a PUCAI score of \<10 points.
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI) | 0.0 (0.0 to 79.3) | 75.0 (40.9 to 92.9) | 77.8 (45.3 to 93.7) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
PUCAI clinical response is defined as a reduction in baseline PUCAI score of ≥20 points.
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants in Clinical Response Based on the PUCAI | 0.0 (0.0 to 79.3) | 75.0 (40.9 to 92.9) | 88.9 (56.5 to 98.0) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 52. ES subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants in Endoscopic Remission | 0.0 (0.0 to 79.3) | 62.5 (30.6 to 86.3) | 55.6 (26.7 to 81.1) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
Symptomatic remission at week 52 is defined as a Mayo score for RB=0, SF=0 or 1 with ≥ 1 point decrease from baseline. SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants in Symptomatic Remission | 0.0 (0.0 to 79.3) | 75.0 (40.9 to 92.9) | 66.7 (35.4 to 87.9) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
Observed height velocity by gender and age group was calculated. Age groups for which this was summarized were 2 to \<8, 8 to \<12, and 12 to \<18. Observed height velocity by gender and age group was calculated at baseline according to the following formula: (Present Height \[cm\] - Previous Height \[cm\])/Interval (months) Between Measurements × 12.
| centimeter per year (cm/year) | OL Induction and Maintenance Period: 5 mg/kg Miri IV | OL Induction and Maintenance Period: 10 mg/kg Miri IV | OL Induction and Maintenance Period: 300 mg Miri IV |
|---|---|---|---|
| Female: 2 - <8 years | NA ± NA | — | — |
| Female: 8 - <12 years | 8.65 ± 3.2 | — | — |
| Female: 12 - <18 years | 4.54 ± 4.2 | 4.14 ± 1.3 | 2.97 ± 0.2 |
| Male: 2 - <8 years | NA ± NA | — | — |
| Male: 8 - <12 years | — | NA ± NA | — |
| Male: 12 - <18 years | 12.67 ± 1.0 | NA ± NA | 3.65 ± 4.3 |
Change from Baseline in body weight by gender and age group was calculated.
| kg | OL Induction and Maintenance Period: 5 mg/kg Miri IV | OL Induction and Maintenance Period: 10 mg/kg Miri IV | OL Induction and Maintenance Period: 300 mg Miri IV |
|---|---|---|---|
| Female: 2 - <8 years | NA ± NA | — | — |
| Female: 8 - <12 years | 8 ± 1.1 | — | — |
| Female: 12 - <18 years | 9 ± 7.1 | 9 ± 3.5 | 8 ± 2.7 |
| Male: 2 - <8 years | NA ± NA | — | — |
| Male: 8 - <12 years | — | NA ± NA | — |
| Male: 12 - <18 years | 13 ± 11.6 | NA ± NA | 2 ± 3.2 |
Histologic-endoscopic mucosal remission is defined as achieving both histologic remission and endoscopic remission. Histologic remission is defined as Geboes histological subscores of 0 for parameters: 2B (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration).
| percentage of participants | Maintenance Period: 50 mg Miri SC Q4W | Maintenance Period: 100 mg Miri SC Q4W | Maintenance Period: 200 mg Miri SC Q4W | Maintenance Period: 10 mg/kg Miri IV/50 mg Miri SC | Maintenance Period: 10 mg/kg Miri IV/100 mg Miri SC | Maintenance Period: 300 mg Miri IV/200 mg Miri SC |
|---|---|---|---|---|---|---|
| Percentage of Participants With Histologic-Endoscopic Mucosal Remission | 0.0 (0.0 to 79.3) | 62.5 (30.6 to 86.3) | 44.4 (18.9 to 73.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 79.3) | 0.0 (0.0 to 39.0) |
The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.
| score on a scale | Open Label Induction Period: 5 mg/kg Miri IV | Open Label Induction Period: 10 mg/kg Miri IV | Open Label Induction Period: 300 mg Miri IV |
|---|---|---|---|
| 2 - <8 years | -3 ± 2.1 | — | — |
| 8 - <12 years | -3 ± 2.1 | NA ± NA | — |
| 12- <18 years | -4 ± 2.7 | -2 ± 1.5 | -1 ± 2.8 |
The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.
| score on a scale | OL Maintenance Period: 50 mg Miri SC | OL Maintenance Period: 100 mg Miri SC | OL Maintenance Period: 200 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SC | OL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SC | OL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC |
|---|---|---|---|---|---|---|
| 2 - <8 years | NA ± NA | NA ± NA | — | 0 ± 0 | — | — |
| 8 - <12 years | — | -2 ± 1.0 | — | — | — | — |
| 12- <18 years | — | -5 ± 3.1 | -4 ± 2.4 | — | NA ± NA | 0 ± 2.6 |
Collected over Induction Period (Up to 12 Weeks), Induction and Maintenance Period (Up to 52 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OL Induction Period: 5 mg/kg Miri IV | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| OL Induction Period: 10 mg/kg Miri IV | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| OL Induction Period: 300 mg Miri IV | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| OL Induction and Maintenance Period: 5 mg/kg Miri IV | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| OL Induction and Maintenance Period: 10 mg/kg Miri IV | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| OL Induction and Maintenance Period: 300 mg Miri IV | 0/11 (0%) | 1/11 (9.1%) | 11/11 (100%) |
| Event | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | OL Induction and Maintenance Period: 5 mg/kg Miri IV | OL Induction and Maintenance Period: 10 mg/kg Miri IV | OL Induction and Maintenance Period: 300 mg Miri IV |
|---|---|---|---|---|---|---|
| Appendicitis noninfectiveGastrointestinal disorders | 0/10 | 0/5 | 0/11 | 0/10 | 1/5 | 0/11 |
| PseudarthrosisMusculoskeletal and connective tissue disorders | 0/10 | 0/5 | 0/11 | 0/10 | 1/5 | 0/11 |
| Colitis ulcerativeGastrointestinal disorders | 0/10 | 0/5 | 0/11 | 0/10 | 0/5 | 1/11 |
| Event | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | OL Induction and Maintenance Period: 5 mg/kg Miri IV | OL Induction and Maintenance Period: 10 mg/kg Miri IV | OL Induction and Maintenance Period: 300 mg Miri IV |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/10 | 1/5 | 0/11 | 2/10 | 2/5 | 2/11 |
| HeadacheNervous system disorders | 3/10 | 0/5 | 1/11 | 3/10 | 0/5 | 2/11 |
| Injection site painGeneral disorders | 0/10 | 0/5 | 0/11 | 2/10 | 1/5 | 3/11 |
| AnaemiaBlood and lymphatic system disorders | 0/10 | 1/5 | 0/11 | 0/10 | 1/5 | 0/11 |
| Growth hormone deficiencyEndocrine disorders | 0/10 | 0/5 | 0/11 | 0/10 | 1/5 | 0/11 |
| DyspepsiaGastrointestinal disorders | 0/10 | 0/5 | 0/11 | 0/10 | 1/5 | 0/11 |
| VomitingGastrointestinal disorders | 1/10 | 0/5 | 1/11 | 2/10 | 0/5 | 1/11 |
| Injection site erythemaGeneral disorders | 0/10 | 0/5 | 0/11 | 1/10 | 1/5 | 0/11 |
| Injection site pruritusGeneral disorders | 0/10 | 0/5 | 0/11 | 1/10 | 1/5 | 0/11 |
| Injection site reactionGeneral disorders | 0/10 | 0/5 | 0/11 | 1/10 | 1/5 | 0/11 |
All randomized participants.
| Age, Continuous(years) | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | Total |
|---|---|---|---|---|
| Mean | 9.6 ± 4.22 | 11.6 ± 1.14 | 14.0 ± 1.26 | 11.80 ± 3.37 |
| Sex: Female, Male(Participants) | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | Total |
|---|---|---|---|---|
| Female | 6 | 3 | 6 | 15 |
| Male | 4 | 2 | 5 | 11 |
| Ethnicity (NIH/OMB)(Participants) | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 0 | 3 |
| Not Hispanic or Latino | 2 | 3 | 8 | 13 |
| Unknown or Not Reported | 5 | 2 | 3 | 10 |
| Race (NIH/OMB)(Participants) | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 2 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 3 | 9 | 17 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | OL Induction Period: 5 mg/kg Miri IV | OL Induction Period: 10 mg/kg Miri IV | OL Induction Period: 300 mg Miri IV | Total |
|---|---|---|---|---|
| Israel | 0 | 0 | 1 | 1 |
| Japan | 1 | 2 | 1 | 4 |
| South Korea | 4 | 0 | 0 | 4 |
| United States | 5 | 3 | 9 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from May 2020 to primary completion in Mar 2023, 33 months.
Results were first posted in Oct 2023, 7 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 33 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab